Periostin Levels do not Distinguish Chronic Obstructive Pulmonary Disease Patients With Frequent and Infrequent Exacerbations
Journal Title: Pulmonary Research and Respiratory Medicine – Open Journal - Year 2016, Vol 3, Issue 2
Abstract
Background Periostin, an extracellular matrix protein, is involved in inflammatory processes of the lung. To date, most studies have focused on periostin in asthma patients, its role in chronic obstructive pulmonary disease (COPD) is less clear and no information has been reported on blood levels of periostin in COPD patients in the context of exacerbation rates. As such, this exploratory study aimed to investigate whether periostin is helpful to distinguish between COPD patients with frequent and infrequent exacerbations. Methods We performed an examination of patients with COPD participating in a COPD cohort study in Switzerland. Periostin levels were determined in serum samples by using a commercially available enzyme-linked immunosorbent assay (ELISA) kit. Patients underwent evaluation of clinical symptoms including exacerbation rate (exacerbation defined by requiring oral corticosteroids and/or antibiotics) and lung function. In a subgroup of patients an annual follow-up was available that was considered in an additional analysis. Results Twenty six patients (global initiative of obstructive lung disease (GOLD) stage 1 none, 31% stage 2, 38% stage 3, 31% stage 4) were included in the analysis. The mean±standard deviation (SD) age of the patients was 63±5.9 years, 16 were males, 24 were smokers or exsmokers. The median (quartiles) post-bronchodilator FEV1% predicted was 36(27/57). There was no significant difference in periostin levels between patients with frequent and infrequent exacerbations. The follow-up data revealed no evidence that periostin is helpful in distinguishing frequent from infrequent exacerbators. Conclusion Our analysis performed in a small group of carefully matched COPD patients demonstrates that there is no significant relationship between exacerbation rate and periostin levels in blood.
Authors and Affiliations
Christian F. Clarenbach
Keywords
Related Articles
- EP ID EP546558
- DOI 10.17140/PRRMOJ-3-129
- Views 161
- Downloads 0
Recent Advances in Pulmonary Rehabilitation for Patients with COPD
Pulmonary rehabilitation (PR) is a non-pharmacologic therapy that has emerged as a standard of care for patients with chronic obstructive pulmonary disease (COPD). It is a comprehensive, multidisciplinary, patient-center...
Pulmonary Endometriosis: A Review
Endometriosis is a benign gynaecological condition whereby endometrial tissue exists outside the uterus in women of reproductive age group. It occurs mainly in the pelvis and rarely extrapelvic areas such as the lungs. P...
Role of MicroRNAs in Progression and Recurrence of Early-Stage Lung Adenocarcinoma
Lung cancer is the leading cause of cancer-related death worldwide, and the majority of cases (77%) are not diagnosed until the disease has spread to regional lymph nodes or distant sites. Even among Non-Small Cell Lung...
Modern Technology in Respiratory Medicine: Lung Ultrasonography–Is it Time for the Stethoscope to Give Up its Throne?
The year 2016 marks the 200th anniversary of the invention of the stethoscope by Dr. Réne Théophile Hyacinthe Laennec. He was first inspired in September 1816 when he observed 2 children playing with a long piece of soli...
A Rare Treatment Modality and its Unusual Complication: Pneumomediastinum and Subcutaneous Emphysema Following Argon Plasma Coagulation
Argon plasma coagulation (APC) is an effective non-contact electrosurgery tool and the use of APC in interventional pulmonology is relatively recent. Successful endobronchial APC has been described in debulking malignant...